<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02153528</url>
  </required_header>
  <id_info>
    <org_study_id>OneRIF</org_study_id>
    <nct_id>NCT02153528</nct_id>
  </id_info>
  <brief_title>Optimization of the TB Treatment Regimen Cascade</brief_title>
  <acronym>OneRIF</acronym>
  <official_title>Optimization of the TB Treatment Regimen Cascade</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Damien Foundation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National TB control Programme Bangladesh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institute of Tropical Medicine, Belgium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Damien Foundation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      - Hypothesis: Double dose rifampicin together with earlier monitoring of sputum conversion
      using vital staining reduces unfavorable outcome of Cat. 1 first-line TB treatment without
      excess serious toxicity, and allows early switch to specific treatment of MDR-TB without
      using Cat. 2 retreatment regimen

      - General study design: This open label, randomised clinical trial is intended as a pilot
      study on the efficacy and safety of high-dose rifampicin and feasibility and added value of
      auramine and/or FDA vital staining sputum smear after 2 weeks of intensive treatment phase.
      If this proof-of-concept study provides substantial indication of benefit without indication
      of excess toxicity, the data from the study will be used to design a larger scale,
      cluster-randomized study. The aim of this cluster randomised study would be to provide
      definite proof of the benefit of the intervention on adverse treatment outcomes and lack of
      excess toxicity associated with high dose rifampicin. In addition, the cluster-randomized
      study would provide a more precise assessment of the suppression and prevention of (acquired)
      resistance endpoints.

      An interim analysis is thus planned at the time the last recruited patient finishes
      treatment, i.e. about 9 months after the end of recruitment. It will focus on assessment of
      drug toxicity versus suggested benefits of the intervention. This analysis will be primarily
      performed for the go/no-go decision and design considerations for the cluster-randomized
      trial. The decision on proceeding to the cluster randomized study will be based on the
      absence of excess toxicity, a trend toward a reduction of unfavourable outcomes (excluding
      relapse), and possible favourable effects on initially present low-resistance mutations /
      mutations acquired during treatment. It will also allow to adapt the design of the larger
      study particularly regarding the algorithm for resistance screening, and whether or not
      treatment shortening could be justified with rapid initial conversion.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2014</start_date>
  <completion_date type="Actual">August 1, 2017</completion_date>
  <primary_completion_date type="Actual">August 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tuberculose Treatment Outcome</measure>
    <time_frame>12 months after end of treatment</time_frame>
    <description>Following current WHO guidelines, an adverse treatment outcome is defined as any occurrence of the following:
Relapse: Cured previously from TB or completed treatment for TB and now having bacteriologically positive sputum for TB (at 12 months follow-up or at an earlier time point)
Default: The patient whose treatment was interrupted for â‰¥ 2 consecutive months.
Failure: Sputum positive for TB at 5 months or later during treatment. In line with current WHO recommendations, patients detected with MDR-TB or rifampicin resistance before this or another outcome applies and switched to the MDR-TB regimen will be excluded from the outcome analysis.18 Failure will also be declared if the regimen has to be changed for at least 2 drugs due to adverse events.
Death: All-cause mortality between case registration and end of TB treatment (related or not to TB or TB treatment)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Develop Liver Toxicity</measure>
    <time_frame>until month eight</time_frame>
    <description>Grade 3-4 Liver Toxicity following NIH common toxicity criteria (CTC), including transaminase increases to &gt;5-20 ULN (grade 3), or &gt; 20 ULN (grade 4)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High-level Rifampicin Resistant TB Adverse Treatment Outcomes</measure>
    <time_frame>12 months after end of TB treatment</time_frame>
    <description>To assess whether the study regimen also cures high-level rifampicin resistant TB. Adverse treatment outcomes will be described and compared among treatment groups in subgroups defined by initial rifampicin resistance mutations (performed in all patients) detected.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Initial Resistant TB Cases Who Switched to MDR-TB Treatment or Were Cured</measure>
    <time_frame>at two weeks of treatment</time_frame>
    <description>To assess the effectiveness of FDA vital staining versus fever screening for early switch of non-responding rifampicin resistant TB to MDR-TB treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the Negative Predictive Value of Conversion at 2 Weeks for Relapse.</measure>
    <time_frame>at 2 weeks of treatment</time_frame>
    <description>The Negative Predictive value (and 95% CI) of conversion in the intervention arm will be estimated as the % of relapses among those with a minimum 1 log decline in the number of AFB, or who are already negative or only scanty positive on AFB smear (auramine or FDA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Acquired Rifampicin Resistance Among Failures and Relapses</measure>
    <time_frame>12 months after end of TB treatment</time_frame>
    <description>number of failure / relapse cases without mutation detected at diagnosis as the denominator and comparing intervention and control arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve of Auramine Resp. FDA at 2 Weeks to Predict Adverse Treatment Outcome at 1 Year After Treatment Completion</measure>
    <time_frame>Auramine/FDA at 2 weeks and adverse treatment outcome 1 year after treatment completion</time_frame>
    <description>Area under the ROC curve (AUC) to predict adverse treatment outcome. The X-axis represents the 1-specificity, the Y-axis represents sensitivity. The AUC is estimated with 95% confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight Gain</measure>
    <time_frame>until end of treatment (month eight)</time_frame>
    <description>Weight gain from baseline until end-of-treatment comparison between both treatment arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fever Resolution</measure>
    <time_frame>after 2 weeks of treatment</time_frame>
    <description>Comparison of fever resolution after 2 weeks of treatment between both treatment arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">701</enrollment>
  <condition>Tuberculosis, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Standard TB treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>double rimfampicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>double rimfampicin</intervention_name>
    <description>Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
    <arm_group_label>double rimfampicin</arm_group_label>
    <other_name>Intervention arm</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard TB treatment</intervention_name>
    <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
    <arm_group_label>Standard TB treatment</arm_group_label>
    <other_name>Control arm</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed with smear-positive pulmonary TB

          -  15 years or older

          -  Able and willing to provide written informed consent

        Exclusion Criteria:

          -  contacts of MDR-TB patients and other MDR-TB suspects diagnosed with resistance on
             rapid DST for rifampicin performed prior to start of treatment according to NTP
             guidelines

          -  smear-negative pulmonary and extra-pulmonary TB cases

          -  patients in need of hospitalization because of very bad general condition or
             complications

          -  patients with clinically active liver disease, for the study defined as jaundice
             confirmed by a local Medical Officer (Government)

          -  any known HIV-positive patient (although none are expected)

          -  any patient with known hepatitis B or C infection

          -  pregnant women; in addition, patients in the intervention arm who become pregnant
             during treatment will be switched to the control arm
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Aung Kya Jai Maug, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Damien Foundation Bangladesh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Damien Foundation Bangladesh TB project in Greater Mymensingh district (8 selected clinics)</name>
      <address>
        <city>Dhaka</city>
        <state>Greater Mymensingh District</state>
        <country>Bangladesh</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bangladesh</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 26, 2014</study_first_submitted>
  <study_first_submitted_qc>May 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 3, 2014</study_first_posted>
  <results_first_submitted>January 15, 2020</results_first_submitted>
  <results_first_submitted_qc>February 11, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 13, 2020</results_first_posted>
  <last_update_submitted>February 11, 2020</last_update_submitted>
  <last_update_submitted_qc>February 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bangladesh</keyword>
  <keyword>Rimfapicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 15, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02153528/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 18, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/28/NCT02153528/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard TB Treatment</title>
          <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
        </group>
        <group group_id="P2">
          <title>Double Rimfampicin</title>
          <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
                <participants group_id="P2" count="353"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="348"/>
                <participants group_id="P2" count="353"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>3 subjects (1 from intervention arm and 2 from control arm) were excluded from the baseline population because they were infected with Non-TB-Mycobacteria (NTM).</population>
      <group_list>
        <group group_id="B1">
          <title>Standard TB Treatment</title>
          <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
        </group>
        <group group_id="B2">
          <title>Double Rimfampicin</title>
          <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="346"/>
            <count group_id="B2" value="352"/>
            <count group_id="B3" value="698"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42" lower_limit="28" upper_limit="55"/>
                    <measurement group_id="B2" value="45" lower_limit="27.5" upper_limit="55"/>
                    <measurement group_id="B3" value="44" lower_limit="28.0" upper_limit="55.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Male</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="251"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="511"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="187"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41" lower_limit="37" upper_limit="46"/>
                    <measurement group_id="B2" value="42" lower_limit="36" upper_limit="46"/>
                    <measurement group_id="B3" value="41.5" lower_limit="36" upper_limit="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="159" lower_limit="153" upper_limit="165"/>
                    <measurement group_id="B2" value="158" lower_limit="152" upper_limit="164"/>
                    <measurement group_id="B3" value="159" lower_limit="152" upper_limit="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Temperature</title>
          <units>Â°F</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99.1" lower_limit="98.3" upper_limit="100.2"/>
                    <measurement group_id="B2" value="99.2" lower_limit="98.5" upper_limit="100.0"/>
                    <measurement group_id="B3" value="99.2" lower_limit="98.4" upper_limit="100.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Direct smear auramine</title>
          <description>200x magnification</description>
          <units>Acid Fast Bacilli/field</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="98" lower_limit="7.0" upper_limit="550.0"/>
                    <measurement group_id="B2" value="90.0" lower_limit="7.0" upper_limit="500"/>
                    <measurement group_id="B3" value="93.3" lower_limit="7.0" upper_limit="525.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intervention smear auramine</title>
          <description>200x magnification</description>
          <units>AFB/field</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">This was only assessed for the intervention arm (double rifampicin).</measurement>
                    <measurement group_id="B2" value="100.0" lower_limit="8.0" upper_limit="575.0"/>
                    <measurement group_id="B3" value="100.0" lower_limit="8.0" upper_limit="575.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Intervention smear FDA</title>
          <description>200x magnification</description>
          <units>number of AFB</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA" lower_limit="NA" upper_limit="NA">Only assessed in het intervention arm (double rifampicin).</measurement>
                    <measurement group_id="B2" value="10.0" lower_limit="0.5" upper_limit="79.5"/>
                    <measurement group_id="B3" value="10.0" lower_limit="0.5" upper_limit="79.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ALT</title>
          <units>IU/L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20" lower_limit="14" upper_limit="33"/>
                    <measurement group_id="B2" value="20" lower_limit="15" upper_limit="29.5"/>
                    <measurement group_id="B3" value="20" lower_limit="15" upper_limit="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>New case of TB</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="326"/>
                    <measurement group_id="B2" value="323"/>
                    <measurement group_id="B3" value="649"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="331"/>
                    <measurement group_id="B2" value="335"/>
                    <measurement group_id="B3" value="666"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Liver problems</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="697"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Kidney problems</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="697"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lung/Heart problems</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="344"/>
                    <measurement group_id="B2" value="349"/>
                    <measurement group_id="B3" value="693"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sign of Hepatitis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="352"/>
                    <measurement group_id="B3" value="698"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Cough</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="346"/>
                    <count group_id="B2" value="352"/>
                    <count group_id="B3" value="698"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="345"/>
                    <measurement group_id="B2" value="351"/>
                    <measurement group_id="B3" value="696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tuberculose Treatment Outcome</title>
        <description>Following current WHO guidelines, an adverse treatment outcome is defined as any occurrence of the following:
Relapse: Cured previously from TB or completed treatment for TB and now having bacteriologically positive sputum for TB (at 12 months follow-up or at an earlier time point)
Default: The patient whose treatment was interrupted for â‰¥ 2 consecutive months.
Failure: Sputum positive for TB at 5 months or later during treatment. In line with current WHO recommendations, patients detected with MDR-TB or rifampicin resistance before this or another outcome applies and switched to the MDR-TB regimen will be excluded from the outcome analysis.18 Failure will also be declared if the regimen has to be changed for at least 2 drugs due to adverse events.
Death: All-cause mortality between case registration and end of TB treatment (related or not to TB or TB treatment)</description>
        <time_frame>12 months after end of treatment</time_frame>
        <population>Intention-to-treat analysis. Additional 4 subjects were removed from the ITT analysis because they switched to MDR regimen (3 in control arm, 1 in intervention arm). 4 subjects (intervention arm) were removed from the ITT analysis because they were enrolled twice.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard TB Treatment</title>
            <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
          </group>
          <group group_id="O2">
            <title>Double Rimfampicin</title>
            <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
          </group>
        </group_list>
        <measure>
          <title>Tuberculose Treatment Outcome</title>
          <description>Following current WHO guidelines, an adverse treatment outcome is defined as any occurrence of the following:
Relapse: Cured previously from TB or completed treatment for TB and now having bacteriologically positive sputum for TB (at 12 months follow-up or at an earlier time point)
Default: The patient whose treatment was interrupted for â‰¥ 2 consecutive months.
Failure: Sputum positive for TB at 5 months or later during treatment. In line with current WHO recommendations, patients detected with MDR-TB or rifampicin resistance before this or another outcome applies and switched to the MDR-TB regimen will be excluded from the outcome analysis.18 Failure will also be declared if the regimen has to be changed for at least 2 drugs due to adverse events.
Death: All-cause mortality between case registration and end of TB treatment (related or not to TB or TB treatment)</description>
          <population>Intention-to-treat analysis. Additional 4 subjects were removed from the ITT analysis because they switched to MDR regimen (3 in control arm, 1 in intervention arm). 4 subjects (intervention arm) were removed from the ITT analysis because they were enrolled twice.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Default</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Died</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Completed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Cured</title>
                  <measurement_list>
                    <measurement group_id="O1" value="310"/>
                    <measurement group_id="O2" value="319"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Develop Liver Toxicity</title>
        <description>Grade 3-4 Liver Toxicity following NIH common toxicity criteria (CTC), including transaminase increases to &gt;5-20 ULN (grade 3), or &gt; 20 ULN (grade 4)</description>
        <time_frame>until month eight</time_frame>
        <population>One participant was allocated to double rifampicin arm but received standard TB treatment, and was analysed in the standard TB treatment arm.Two participants were deleted from analysis because they had grade 3 liver toxicity at baseline and 6 participants were deleted because they did not have any follow-up ALT values.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard TB Treatment</title>
            <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
          </group>
          <group group_id="O2">
            <title>Double Rimfampicin</title>
            <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Develop Liver Toxicity</title>
          <description>Grade 3-4 Liver Toxicity following NIH common toxicity criteria (CTC), including transaminase increases to &gt;5-20 ULN (grade 3), or &gt; 20 ULN (grade 4)</description>
          <population>One participant was allocated to double rifampicin arm but received standard TB treatment, and was analysed in the standard TB treatment arm.Two participants were deleted from analysis because they had grade 3 liver toxicity at baseline and 6 participants were deleted because they did not have any follow-up ALT values.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="343"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High-level Rifampicin Resistant TB Adverse Treatment Outcomes</title>
        <description>To assess whether the study regimen also cures high-level rifampicin resistant TB. Adverse treatment outcomes will be described and compared among treatment groups in subgroups defined by initial rifampicin resistance mutations (performed in all patients) detected.</description>
        <time_frame>12 months after end of TB treatment</time_frame>
        <population>ITT analysis population. Compared to analysis population of primary objective - TB treatment outcome, 24 subjects were excluded from this analysis due to missing or negative sequencing results (8 in control group, 16 in intervention group).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard TB Treatment</title>
            <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
          </group>
          <group group_id="O2">
            <title>Double Rimfampicin</title>
            <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
          </group>
        </group_list>
        <measure>
          <title>High-level Rifampicin Resistant TB Adverse Treatment Outcomes</title>
          <description>To assess whether the study regimen also cures high-level rifampicin resistant TB. Adverse treatment outcomes will be described and compared among treatment groups in subgroups defined by initial rifampicin resistance mutations (performed in all patients) detected.</description>
          <population>ITT analysis population. Compared to analysis population of primary objective - TB treatment outcome, 24 subjects were excluded from this analysis due to missing or negative sequencing results (8 in control group, 16 in intervention group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="335"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Rif-sensitive with adverse treatment outcome</title>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rif-sensitive cured/completed without relapse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="281"/>
                    <measurement group_id="O2" value="290"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rif-resistant with adverse treatment outcome</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rif-resistant cured/completed without relapse</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Initial Resistant TB Cases Who Switched to MDR-TB Treatment or Were Cured</title>
        <description>To assess the effectiveness of FDA vital staining versus fever screening for early switch of non-responding rifampicin resistant TB to MDR-TB treatment</description>
        <time_frame>at two weeks of treatment</time_frame>
        <population>7 initial resistant cases (5 in control group and 2 in intervention group).</population>
        <group_list>
          <group group_id="O1">
            <title>Standard TB Treatment</title>
            <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
          </group>
          <group group_id="O2">
            <title>Double Rimfampicin</title>
            <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Initial Resistant TB Cases Who Switched to MDR-TB Treatment or Were Cured</title>
          <description>To assess the effectiveness of FDA vital staining versus fever screening for early switch of non-responding rifampicin resistant TB to MDR-TB treatment</description>
          <population>7 initial resistant cases (5 in control group and 2 in intervention group).</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Negative Predictive Value of Conversion at 2 Weeks for Relapse.</title>
        <description>The Negative Predictive value (and 95% CI) of conversion in the intervention arm will be estimated as the % of relapses among those with a minimum 1 log decline in the number of AFB, or who are already negative or only scanty positive on AFB smear (auramine or FDA).</description>
        <time_frame>at 2 weeks of treatment</time_frame>
        <population>ITT analysis. This analysis only includes participants in the intervention arm who are negative on auramine smear resp. FDA smear at 2 weeks.</population>
        <group_list>
          <group group_id="O1">
            <title>Double Rifampicin Arm Negative on Auramine Smear</title>
            <description>This outcome is only calculated for the intervention arm.</description>
          </group>
          <group group_id="O2">
            <title>Double Rifampicin Group Negative on FDA Smear</title>
            <description>This outcome is only analysed for the intervention arm.</description>
          </group>
        </group_list>
        <measure>
          <title>the Negative Predictive Value of Conversion at 2 Weeks for Relapse.</title>
          <description>The Negative Predictive value (and 95% CI) of conversion in the intervention arm will be estimated as the % of relapses among those with a minimum 1 log decline in the number of AFB, or who are already negative or only scanty positive on AFB smear (auramine or FDA).</description>
          <population>ITT analysis. This analysis only includes participants in the intervention arm who are negative on auramine smear resp. FDA smear at 2 weeks.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
                <count group_id="O2" value="193"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Acquired Rifampicin Resistance Among Failures and Relapses</title>
        <description>number of failure / relapse cases without mutation detected at diagnosis as the denominator and comparing intervention and control arms.</description>
        <time_frame>12 months after end of TB treatment</time_frame>
        <population>ITT analysis. This analysis only includes failure / relapse cases without mutation detected at diagnosis</population>
        <group_list>
          <group group_id="O1">
            <title>Standard TB Treatment</title>
            <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
          </group>
          <group group_id="O2">
            <title>Double Rimfampicin</title>
            <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Acquired Rifampicin Resistance Among Failures and Relapses</title>
          <description>number of failure / relapse cases without mutation detected at diagnosis as the denominator and comparing intervention and control arms.</description>
          <population>ITT analysis. This analysis only includes failure / relapse cases without mutation detected at diagnosis</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Curve of Auramine Resp. FDA at 2 Weeks to Predict Adverse Treatment Outcome at 1 Year After Treatment Completion</title>
        <description>Area under the ROC curve (AUC) to predict adverse treatment outcome. The X-axis represents the 1-specificity, the Y-axis represents sensitivity. The AUC is estimated with 95% confidence interval.</description>
        <time_frame>Auramine/FDA at 2 weeks and adverse treatment outcome 1 year after treatment completion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Double Rifampicin Arm Negative on Auramine Smear</title>
            <description>This outcome is only calculated for the intervention arm.</description>
          </group>
          <group group_id="O2">
            <title>Double Rifampicin Group Negative on FDA Smear</title>
            <description>This outcome is only analysed for the intervention arm.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve of Auramine Resp. FDA at 2 Weeks to Predict Adverse Treatment Outcome at 1 Year After Treatment Completion</title>
          <description>Area under the ROC curve (AUC) to predict adverse treatment outcome. The X-axis represents the 1-specificity, the Y-axis represents sensitivity. The AUC is estimated with 95% confidence interval.</description>
          <units>no unit is used for AUROC</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="344"/>
                <count group_id="O2" value="344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" lower_limit="0.42" upper_limit="0.61"/>
                    <measurement group_id="O2" value="0.54" lower_limit="0.45" upper_limit="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Weight Gain</title>
        <description>Weight gain from baseline until end-of-treatment comparison between both treatment arms.</description>
        <time_frame>until end of treatment (month eight)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Standard TB Treatment</title>
            <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
          </group>
          <group group_id="O2">
            <title>Double Rimfampicin</title>
            <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
          </group>
        </group_list>
        <measure>
          <title>Weight Gain</title>
          <description>Weight gain from baseline until end-of-treatment comparison between both treatment arms.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="320"/>
                <count group_id="O2" value="331"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.93" spread="2.44"/>
                    <measurement group_id="O2" value="2.79" spread="2.44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fever Resolution</title>
        <description>Comparison of fever resolution after 2 weeks of treatment between both treatment arms.</description>
        <time_frame>after 2 weeks of treatment</time_frame>
        <population>Total of participants with fever at baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Standard TB Treatment</title>
            <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
          </group>
          <group group_id="O2">
            <title>Double Rimfampicin</title>
            <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
          </group>
        </group_list>
        <measure>
          <title>Fever Resolution</title>
          <description>Comparison of fever resolution after 2 weeks of treatment between both treatment arms.</description>
          <population>Total of participants with fever at baseline.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="82"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events are recorded until end of treatment (up to 8 months). No (non-serious) adverse events are recorded in this trial.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard TB Treatment</title>
          <description>Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
Standard TB treatment: Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease</description>
        </group>
        <group group_id="E2">
          <title>Double Rimfampicin</title>
          <description>2HREZ/4HR Cat. 1, modified by using double dose rifampicin throughout
double rimfampicin: Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Anuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Victim of homicide</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="348"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="353"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trials Unit ITM</name_or_title>
      <organization>Institute of Tropical Medicine Antwerp</organization>
      <phone>0032 32470778</phone>
      <email>jbuyze@itg.be</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

